Ryvu Therapeutics Valuation
Is 9Y4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9Y4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9Y4's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9Y4's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9Y4?
Key metric: As 9Y4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 9Y4's PS Ratio? | |
|---|---|
| PS Ratio | 11.4x |
| Sales | zł91.18m |
| Market Cap | zł1.04b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.6x |
| Enterprise Value/EBITDA | -9.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 9Y4's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.1x | ||
EVT Evotec | 2.1x | 12.1% | €1.7b |
GXI Gerresheimer | 1.3x | 10.3% | €2.6b |
1SXP SCHOTT Pharma KGaA | 4.3x | 10.7% | €4.0b |
SRT3 Sartorius | 4.5x | 9.3% | €13.6b |
9Y4 Ryvu Therapeutics | 11.4x | 14.9% | €1.0b |
Price-To-Sales vs Peers: 9Y4 is expensive based on its Price-To-Sales Ratio (11.4x) compared to the peer average (3.1x).
Price to Sales Ratio vs Industry
How does 9Y4's PS Ratio compare vs other companies in the European Life Sciences Industry?
| 6 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 6 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 9Y4 is expensive based on its Price-To-Sales Ratio (11.4x) compared to the European Life Sciences industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is 9Y4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 11.4x |
| Fair PS Ratio | 2.3x |
Price-To-Sales vs Fair Ratio: 9Y4 is expensive based on its Price-To-Sales Ratio (11.4x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €9.96 | €18.78 +88.5% | 20.4% | €25.09 | €15.55 | n/a | 4 |
| Nov ’25 | €10.38 | €18.44 +77.6% | 16.4% | €23.26 | €15.70 | n/a | 4 |
| Oct ’25 | €11.88 | €18.44 +55.2% | 16.4% | €23.26 | €15.70 | n/a | 4 |
| Sep ’25 | €12.18 | €17.81 +46.2% | 17.5% | €22.68 | €14.62 | n/a | 4 |
| Aug ’25 | €11.60 | €17.81 +53.5% | 17.5% | €22.68 | €14.62 | n/a | 4 |
| Jul ’25 | €11.34 | €17.81 +57.0% | 17.5% | €22.68 | €14.62 | n/a | 4 |
| Jun ’25 | €12.34 | €16.56 +34.2% | 9.5% | €18.70 | €14.96 | n/a | 3 |
| May ’25 | €11.04 | €16.96 +53.7% | 9.7% | €18.56 | €14.85 | n/a | 4 |
| Apr ’25 | €12.54 | €16.78 +33.8% | 8.5% | €18.68 | €14.94 | n/a | 4 |
| Mar ’25 | €13.42 | €16.94 +26.2% | 9.7% | €18.53 | €14.82 | n/a | 4 |
| Feb ’25 | €12.86 | €16.44 +27.8% | 12.1% | €18.41 | €14.20 | n/a | 4 |
| Jan ’25 | €13.48 | €16.44 +22.0% | 12.1% | €18.41 | €14.20 | n/a | 4 |
| Dec ’24 | €12.88 | €16.44 +27.6% | 12.1% | €18.41 | €14.20 | n/a | 4 |
| Nov ’24 | €13.56 | €15.80 +16.5% | 10.5% | €17.95 | €13.84 | €10.38 | 4 |
| Oct ’24 | €13.12 | €15.62 +19.1% | 11.1% | €17.44 | €13.28 | €11.88 | 3 |
| Sep ’24 | €12.76 | €16.45 +28.9% | 11.1% | €18.36 | €13.98 | €12.18 | 3 |
| Aug ’24 | €12.90 | €16.45 +27.5% | 11.1% | €18.36 | €13.98 | €11.60 | 3 |
| Jul ’24 | €12.86 | €15.71 +22.2% | 10.7% | €17.40 | €13.42 | €11.34 | 3 |
| Jun ’24 | €11.86 | €15.71 +32.5% | 10.7% | €17.40 | €13.42 | €12.34 | 3 |
| May ’24 | €11.94 | €15.71 +31.6% | 10.7% | €17.40 | €13.42 | €11.04 | 3 |
| Apr ’24 | €12.06 | €15.45 +28.1% | 10.7% | €17.11 | €13.20 | €12.54 | 3 |
| Mar ’24 | €12.56 | €13.17 +4.9% | 21.5% | €16.75 | €9.84 | €13.42 | 3 |
| Feb ’24 | €11.00 | €11.76 +6.9% | 15.6% | €13.60 | €9.92 | €12.86 | 2 |
| Jan ’24 | €10.38 | €11.76 +13.3% | 15.6% | €13.60 | €9.92 | €13.48 | 2 |
| Dec ’23 | €11.46 | €11.76 +2.6% | 15.6% | €13.60 | €9.92 | €12.88 | 2 |
| Nov ’23 | €8.69 | €11.76 +35.3% | 15.6% | €13.60 | €9.92 | €13.56 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.9b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$16.05
7D
4.9%
1Y
79.5%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$28.60
7D
2.1%
1Y
21.2%